EUROPE DNA VACCINE MARKET FORECAST 2018-2026

EUROPE DNA VACCINE MARKET FORECAST 2018-2026

  • April 2018 •
  • 85 pages •
  • Report ID: 5129380 •
  • Format: PDF
KEY FINDINGS
Europe DNA vaccine market is predicted to rise with a CAGR of 41.34%, increasing its revenue from $XX million to $XX million over the forecast period of 2018-2026.

MARKET INSIGHTS
The fact that these vaccines are increasingly being adopted for veterinary purposes and are highly useful for keeping in check the growing prevalence of diseases is significantly driving the market growth.Also, the third-generation vaccines have witnessed a rise in the number of investments in recent years, which is a very good news for the market.

Still, there are factors like lengthy regulatory process and weak patent protection laws, coupled with the fact that the vaccines for humans are still under clinical trials, which are significantly holding back the market potential.

COMPETITIVE INSIGHTS
Some of the renowned players in the market are Vical Incorporated, Eurogentec S.A, Inovio Pharmaceuticals Inc, Sanofi, Madison Vaccines Incorporated (MVI), Astellas Pharma Inc, Merck & Co, Eli Lilly And Company, Glaxosmithkline Inc, Novartis Ag, and Xenetic Biosciences Inc.